Nesvacumab information

Nesvacumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Angiopoietin 2
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
CAS Number	1296818-77-3;
IUPHAR/BPS	8457;
ChemSpider	none;
UNII	WX8293WGLC;
KEGG	D10395;
Chemical and physical data
Formula	C6440H9966N1722O2008S38
Molar mass	144860.89 g·mol−1

Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.^[1]^[2] As of May 2017^[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.^[3]^[4]

This drug is being developed by Regeneron Pharmaceuticals.^{[citation needed]}

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.
^ Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.
^ Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov
^ Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association.

[Hussain_2019-2] Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA (October 2019). "Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease". Expert Opinion on Investigational Drugs. 28 (10): 861–869. doi:10.1080/13543784.2019.1667333. PMID 31513439.

[3] Clinical trial number NCT02713204 for "Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)" at ClinicalTrials.gov

[4] Clinical trial number NCT02712008 for "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)" at ClinicalTrials.gov

Nesvacumab information

and 25 Related for: Nesvacumab information

Nesvacumab

Dexamethasone

Testosterone

Erythropoietin

Amitriptyline

Insulin

Fruquintinib

Nerve growth factor

Dehydroepiandrosterone

Osimertinib

Epidermal growth factor

Repotrectinib

HER2

Nintedanib

Neurotrophic factors

Alectinib

Cetuximab

Bevacizumab

Imatinib

Cabozantinib

Epidermal growth factor receptor

Wnt signaling pathway

Neurotrophin

Fibroblast growth factor

Faricimab